A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most commo...
Comprehensive, easy-to-understand information about this condition
How we create this content →Connect with organizations supporting the cancer community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Connect with organizations supporting the cancer community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Connect with organizations supporting the cancer community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 1, 2026
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning cancer
Updated Feb 6, 2026
Between 2011 and 2020, 410 new molecular entities were approved by the FDA, reflecting a 6.5% growth in the US. Globally, expedited approval programs have been crucial for anticancer drugs, with 9-75% receiving such designations in Europe, and China implementing similar pathways to enhance pharmaceutical development.
In 2024, the biotech sector has seen 47 M&A and IPO deals totaling $53 billion, with 15 exceeding $1 billion. Notably, cancer, rare diseases, and cell therapies are key areas attracting investment.
A systematic review and meta-analysis reveals the global prevalence of peripheral neuropathy in cancer patients post-chemotherapy. This study highlights the significant impact of chemotherapy on nerve health, emphasizing the need for better management strategies.
Eikon Therapeutics raised $381 million in its IPO to advance its lead cancer immunotherapy program currently in clinical trials. The offering included 21.2 million shares priced at $18 each, reflecting strong investor interest in the biotech sector.
Novartis has cut six early-stage cancer candidates while adding two to refine its oncology strategy. CEO Vas Narasimhan emphasized ongoing investment in the early-stage pipeline and a focus on deals under $2 billion.